A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029)

A Phase I Clinical Study of L-001079038 in Patients With Solid Tumors

The primary purpose of this trial is to determine the maximum tolerated dose (MTD), or the maximum acceptable dose (MAD) and evaluate the dose limiting toxicity (DLT) of oral suberoylanilide hydroxamic acid in participants with solid tumors.

Inclusion Criteria:

• Participants with histologically or cytologically diagnosed solid tumor; no standard therapy available or participant has failed to respond to standard therapy

Exclusion Criteria:

• Participants with history of immunotherapy, radiotherapy, surgery, or chemotherapy during the previous 4 weeks; previous treatment is 5 or more chemotherapeutic regimens.
• Any uncontrolled concomitant illness
• Are pregnant or breast-feeding
• Serious drug or food allergy